## AFL: Aflac Incorporated - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Caution: momentum weakening (-1.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($105.86)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Ameriflex, Aflac (AFL) team up to deliver CDH and spending account admin for public sector**
- Source: Stock Titan | 20251202T090000 | Bullish | Relevance: 100%
- Ameriflex and Aflac have announced a partnership where Ameriflex will administer consumer-directed health (CDH) services for Aflac in the public sector market. This collaboration aims to provide seamless delivery of spending accounts like FSAs and HSAs, enhancing Aflac's offerings and customer experience for public sector clients. Both companies emphasize their shared commitment to excellent service and innovative solutions to deliver value and financial protection.

**2. Aflac Incorporated $AFL Position Reduced by First Trust Advisors LP**
- Source: MarketBeat | 20251204T100806 | Somewhat-Bullish | Relevance: 100%
- First Trust Advisors LP reduced its stake in Aflac Incorporated (NYSE:AFL) by 13.1% in the second quarter, selling 582,563 shares and now owning 3,854,930 shares valued at approximately $406.54 million. Despite this reduction, Aflac announced an increase in its quarterly dividend to $0.61 per share and approved a 100,000,000 share buyback program. Analysts currently have an average "Hold" rating on Aflac with a target price of $111.00.

**3. Northwestern Mutual Wealth Management Co. Purchases 10,120 Shares of Aflac Incorporated $AFL**
- Source: MarketBeat | 20251204T040959 | Somewhat-Bullish | Relevance: 100%
- Northwestern Mutual Wealth Management Co. increased its stake in Aflac Incorporated by 12.3% in Q2, acquiring an additional 10,120 shares to own a total of 92,718 shares valued at approximately $9.78 million. Aflac has also announced a quarterly dividend increase to $0.61 and authorized a share buyback program for 100 million shares, indicating a strong commitment to shareholder returns. Analyst ratings for Aflac are currently mixed, with a consensus "Hold" rating and an average price target of $111.

**4. Is Aflac Stock Underperforming the Nasdaq?**
- Source: inkl | 20251202T122131 | Somewhat-Bearish | Relevance: 100%
- Aflac (AFL) is underperforming the Nasdaq, with its stock up only 2.5% in the last three months compared to the Nasdaq Composite's 8.5% rise. Despite long-term underperformance relative to the Nasdaq, Aflac has outperformed peer MetLife (MET) and maintains a consensus "Hold" rating with analysts. The company recently declared a dividend increase, marking its 43rd consecutive year of dividend growth.

**5. Ameriflex and Aflac Partner to Deliver Seamless Consumer Directed Health Care Administration in the Public Sector Market**
- Source: Yahoo Finance | 20251202T080000 | Bullish | Relevance: 100%
- Ameriflex and Aflac have partnered to streamline consumer-directed health care (CDH) administration in the public sector market. Ameriflex will serve as Aflac's administrative partner for CDH services, initially focusing on spending accounts like FSAs and HSAs. This collaboration aims to provide enhanced customer experience and deliver comprehensive benefit administration solutions to Aflac's public sector clients.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-17 | Morgan Stanley | $118 | $113 | +4% |
| 2025-11-07 | Wells Fargo | $109 | $107 | +2% |
| 2025-11-07 | Evercore ISI Gr | $111 | $110 | +1% |
| 2025-11-05 | JP Morgan | $101 | $100 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-17 | Morgan Stanley | main | Equal-Weight |
| 2025-11-07 | Wells Fargo | main | Equal-Weight |
| 2025-11-07 | Evercore ISI Gr | main | Underperform |
| 2025-11-05 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.18M) |
| Sells | 10 ($3.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Japan Post Holdings : 10.0% (0.0%)
- Vanguard Group Inc: 9.6% (-0.8%)
- Blackrock Inc.: 7.4% (+0.1%)
- State Street Corpora: 4.6% (+0.1%)
- Wells Fargo & Compan: 2.1% (-24.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +2%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Quality metrics strong (margin 24%). Balance sheet: strong liquidity (48.2x). Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $58.8B |
| Beta | 0.66 |
| 52W Range | $96.95 - $115.84 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 14.8 |
| Current P/E | 14.4 |
| YoY Growth | -2.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -2.1% to -4.0% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). Underperforming sector by 4.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 45. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.00% (CS: 14) | Weak |
| RSI_14 | 44.6 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.978x | Below |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 1.024x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $109.24
- **Stop Loss:** $105.86 (3.1% risk)
- **Target:** $116.00 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 295
- **Position Value:** $32,225.80
- **Portfolio %:** 32.23%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-04 (Est: $1.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $2.49 | +40.2% |
| 2025Q2 | $1.71 | $1.78 | +4.3% |
| 2025Q1 | $1.67 | $1.66 | -0.8% |
| 2024Q4 | $1.62 | $1.56 | -3.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*